Tabula Rasa HealthCare (Nasdaq:TRHC) - Cotización, noticias y análisis

Resumen de acción TRHC

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States.

TRHC fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 13.23%

Análisis de riesgos

Patrimonio neto negativo

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Tabula Rasa HealthCare, Inc.

Sharecare

NasdaqGS:SHCR

US$293.4m

Health Catalyst

NasdaqGS:HCAT

US$353.1m

American Well

NYSE:AMWL

US$156.3m

SOPHiA GENETICS

NasdaqGS:SOPH

US$328.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Tabula Rasa HealthCare
Historical stock prices
Current Share Price	US$10.50
52 Week High	US$10.50
52 Week Low	US$3.15
Beta	1.58
1 Month Change	1.16%
3 Month Change	34.10%
1 Year Change	203.47%
3 Year Change	-70.13%
5 Year Change	-85.61%
Change since IPO	-29.44%

Noticias y actualizaciones recientes

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

Rentabilidad de los accionistas

	TRHC	US Healthcare Services	Mercado US
7D	0.9%	0.7%	2.9%
1Y	203.5%	-10.0%	22.2%

Rentabilidad vs. Industria: TRHC superó al sector US Healthcare Services , que obtuvo un rendimiento del -13.6% el año pasado.

Rentabilidad vs. Mercado: TRHC superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is TRHC's price volatile compared to industry and market?
TRHC volatility
TRHC Average Weekly Movement	8.6%
Healthcare Services Industry Average Movement	9.9%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de TRHC ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de TRHC (9%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2009	1,027	Brian Adams	www.tabularasahealthcare.com

Resumen de fundamentos de Tabula Rasa HealthCare, Inc.

¿Cómo se comparan los beneficios e ingresos de Tabula Rasa HealthCare con su capitalización de mercado?
Estadísticas fundamentales de TRHC
Capitalización bursátil	US$284.03m
Beneficios(TTM)	-US$61.07m
Ingresos (TTM)	US$338.12m

0.8x

Ratio precio-ventas (PS)

-4.7x

Ratio precio-beneficio (PE)

¿Está TRHC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de TRHC
Ingresos	US$338.12m
Coste de los ingresos	US$258.28m
Beneficio bruto	US$79.84m
Otros gastos	US$140.91m
Beneficios	-US$61.07m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.26
Margen bruto	23.61%
Margen de beneficio neto	-18.06%
Ratio deuda/patrimonio	-418.7%

¿Cómo se ha desempeñado TRHC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción TRHC

Recompensas

Análisis de riesgos

Competidores de Tabula Rasa HealthCare, Inc.

NasdaqGS:SHCR

US$293.4m

NasdaqGS:HCAT

US$353.1m

NYSE:AMWL

US$156.3m

NasdaqGS:SOPH

US$328.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching

Insufficient new directors